{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Levodopa+Induced+Dyskinesia",
    "query": {
      "condition": "Levodopa Induced Dyskinesia"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 33,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Levodopa+Induced+Dyskinesia&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-11T07:09:53.443Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05766813",
      "title": "Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "Lenrispodun",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Intra-Cellular Therapies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 79,
      "start_date": "2023-03-13",
      "completion_date": "2025-11-04",
      "has_results": false,
      "last_update_posted_date": "2026-05-27",
      "last_synced_at": "2026-06-11T07:09:53.443Z",
      "location_count": 35,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Irvine, California + 31 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Altamonte Springs",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05766813"
    },
    {
      "nct_id": "NCT05116813",
      "title": "Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Parkinson Disease",
        "Dyskinesia, Drug-Induced",
        "Dyskinesias"
      ],
      "interventions": [
        {
          "name": "Dipraglurant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Addex Pharma S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "30 Years to 85 Years"
      },
      "enrollment_count": 17,
      "start_date": "2021-10-25",
      "completion_date": "2022-08-15",
      "has_results": false,
      "last_update_posted_date": "2025-08-06",
      "last_synced_at": "2026-06-11T07:09:53.443Z",
      "location_count": 7,
      "location_summary": "Augusta, Georgia • Kansas City, Kansas • New Brunswick, New Jersey + 4 more",
      "locations": [
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05116813"
    },
    {
      "nct_id": "NCT01767129",
      "title": "Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dyskinesia",
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "AVP-923-45",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Avanir Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "30 Years to 80 Years"
      },
      "enrollment_count": 14,
      "start_date": "2013-10-16",
      "completion_date": "2015-02-05",
      "has_results": true,
      "last_update_posted_date": "2022-04-29",
      "last_synced_at": "2026-06-11T07:09:53.443Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • Portland, Oregon",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01767129"
    },
    {
      "nct_id": "NCT01397422",
      "title": "Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Dyskinesia",
        "Levodopa Induced Dyskinesia",
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "ADS-5102 (extended release amantadine HCl)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Adamas Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "30 Years to 85 Years"
      },
      "enrollment_count": 83,
      "start_date": "2011-07",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2017-12-13",
      "last_synced_at": "2026-06-11T07:09:53.443Z",
      "location_count": 33,
      "location_summary": "Sun City, Arizona • Fountain Valley, California • Long Beach, California + 30 more",
      "locations": [
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oxnard",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01397422"
    },
    {
      "nct_id": "NCT00957918",
      "title": "Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "nicotine",
          "type": "DRUG"
        },
        {
          "name": "placebo comparator",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Neuraltus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "83 Years",
        "sex": "ALL",
        "summary": "30 Years to 83 Years"
      },
      "enrollment_count": 65,
      "start_date": "2009-10",
      "completion_date": "2010-09",
      "has_results": false,
      "last_update_posted_date": "2011-10-05",
      "last_synced_at": "2026-06-11T07:09:53.443Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Los Angelis, California • Oxnard, California + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angelis",
          "state": "California"
        },
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00957918"
    },
    {
      "nct_id": "NCT00758368",
      "title": "Comparison of Continuous and Pulsatile Apomorphine in Parkinson's Disease",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "Apomorphine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2009-03",
      "completion_date": "2011-06",
      "has_results": false,
      "last_update_posted_date": "2018-11-02",
      "last_synced_at": "2026-06-11T07:09:53.443Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00758368"
    },
    {
      "nct_id": "NCT02136914",
      "title": "ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dyskinesia",
        "Levodopa Induced Dyskinesia (LID)",
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "ADS-5102",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Adamas Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "30 Years to 85 Years"
      },
      "enrollment_count": 126,
      "start_date": "2014-05",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2018-02-06",
      "last_synced_at": "2026-06-11T07:09:53.443Z",
      "location_count": 43,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 37 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02136914"
    },
    {
      "nct_id": "NCT01003002",
      "title": "Natural History of Levodopa-Induced Dyskinesia (LID)",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "Levodopa (delivered intravenously)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "21 Years to 100 Years"
      },
      "enrollment_count": 0,
      "start_date": "2010-12",
      "completion_date": "2020-12",
      "has_results": false,
      "last_update_posted_date": "2016-04-06",
      "last_synced_at": "2026-06-11T07:09:53.443Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01003002"
    },
    {
      "nct_id": "NCT04435431",
      "title": "A Clinical Study of Mesdopetam in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "Mesdopetam",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Integrative Research Laboratories AB",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "30 Years to 79 Years"
      },
      "enrollment_count": 155,
      "start_date": "2020-10-29",
      "completion_date": "2022-12-09",
      "has_results": true,
      "last_update_posted_date": "2024-03-06",
      "last_synced_at": "2026-06-11T07:09:53.443Z",
      "location_count": 14,
      "location_summary": "Scottsdale, Arizona • Long Beach, California • Palo Alto, California + 9 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04435431"
    },
    {
      "nct_id": "NCT02153645",
      "title": "Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Parkinson's Disease",
        "Levodopa Induced Dyskinesias (LID)"
      ],
      "interventions": [
        {
          "name": "240mg Amantadine HCl ER tablets",
          "type": "DRUG"
        },
        {
          "name": "Placebo tablets",
          "type": "DRUG"
        },
        {
          "name": "320mg Amantadine HCl ER tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Adamas Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "30 Years to 85 Years"
      },
      "enrollment_count": 87,
      "start_date": "2014-08-18",
      "completion_date": "2016-05-20",
      "has_results": true,
      "last_update_posted_date": "2022-02-16",
      "last_synced_at": "2026-06-11T07:09:53.443Z",
      "location_count": 26,
      "location_summary": "Tucson, Arizona • Fountain Valley, California • Irvine, California + 21 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Reseda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02153645"
    }
  ]
}